Antiretroviral drug resistance testing in adults with HIV infection -: Implications for clinical management

被引:492
|
作者
Hirsch, MS
Conway, B
D'Aquila, RT
Johnson, VA
Brun-Vézinet, F
Clotet, B
Demeter, LM
Hammer, SM
Jacobsen, DM
Kuritzkes, DR
Loveday, C
Mellors, JW
Vella, S
Richman, DD
机构
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Infectious Dis Unit, Boston, MA 02114 USA
[3] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[4] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[5] Vet Affairs Med Ctr, Birmingham, AL USA
[6] Hop Bichat Claude Bernard, F-75877 Paris 18, France
[7] Hosp Badalona Germans Trias & Pujol, Fdn Irsa Caixa, Barcelona, Spain
[8] Hosp Badalona Germans Trias & Pujol, HIV Unit, Barcelona, Spain
[9] Univ Rochester, Rochester, NY 14627 USA
[10] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[11] Royal Free Hosp, Sch Med, London, England
[12] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA
[13] Ist Super Sanita, I-00161 Rome, Italy
[14] Univ Calif San Diego, San Diego, CA 92103 USA
[15] Vet Affairs Med Ctr, San Diego, CA 92161 USA
[16] Int AIDS Soc USA, San Francisco, CA 94129 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 279卷 / 24期
关键词
D O I
10.1001/jama.279.24.1984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives.-To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice. Participants.-The international AIDS Society-USA assembled a panel of 13 physicians with expertise in basic science, clinical research, and patient care relevant to HIV resistance to antiretroviral drugs. Evidence.-We reviewed available data from published reports and presented at national and international research conferences. Basic science research, clinical trial results, and expert opinions were used to form the basis of this report, Data on methods for and characteristics of specific genotypic and phenotypic assays were obtained from manufacturers and service providers. Consensus Process.-The panel met regularly between October 1997 and April 1998, Panel subgroups developed and discussed different sections of the report before discussing them with the entire panel. Conclusions and suggested approaches to the use of resistance testing were determined by group consensus. Conclusions.-Plasma HIV RNA level and CD4(+) cell count are the primary values that should be used to guide the initiation of antiretroviral therapy and subsequent changes in therapy. Possible causes of treatment failure other than development of drug resistance that should be considered are adherence, drug potency, and pharmacokinetic issues, Genotypic and phenotypic testing for HIV resistance to antiretroviral drugs may prove useful for individual patient management. Assays under development need validation, standardization, and a clearer definition of their clinical roles, Possible current roles of resistance testing for choosing an initial regimen or changing antiretroviral therapy, as well as possible implications of the presence or absence of phenotypic resistance and genotypic changes, are discussed.
引用
收藏
页码:1984 / 1991
页数:8
相关论文
共 50 条
  • [1] HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance
    Nichols, B. E.
    Boucher, C. A. B.
    van de Vijver, D. A. M. C.
    JOURNAL OF INTERNAL MEDICINE, 2011, 270 (06) : 532 - 549
  • [2] Issues on drug resistance testing in relation to Antiretroviral clinical management
    Asthana, Deshratn
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S21 - S21
  • [3] Issues on Drug Resistance Testing in Relation to Antiretroviral Clinical Management
    Asthana, Deshratn
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S21 - S21
  • [4] Drug resistance in antiretroviral therapy of HIV infection
    Oette, M
    Häussinger, D
    MEDIZINISCHE KLINIK, 2003, 98 (12) : 692 - 699
  • [5] Clinical monitoring of HIV-1 infection in the era of antiretroviral resistance testing
    Kartsonis, NA
    D'Aquila, RT
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2000, 14 (04) : 879 - +
  • [6] The utility of resistance testing in the clinical management of HIV-1 infection
    Bonsall, D.
    Bradshaw, D.
    Mandalia, S.
    Nelson, M.
    HIV MEDICINE, 2012, 13 : 70 - 71
  • [7] Public health implications of antiretroviral therapy and HIV drug resistance
    Wainberg, MA
    Friedland, G
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (24): : 1977 - 1983
  • [8] Clinical Management of HIV Drug Resistance
    Cortez, Karoll J.
    Maldarelli, Frank
    VIRUSES-BASEL, 2011, 3 (04): : 347 - 378
  • [9] Antiretroviral drug resistance testing
    Sen, S.
    Tripathy, S. P.
    Paranjape, R. S.
    JOURNAL OF POSTGRADUATE MEDICINE, 2006, 52 (03) : 187 - 193
  • [10] HIV drug resistance among adults initiating antiretroviral therapy in Uganda
    Watera, Christine
    Ssemwanga, Deogratius
    Namayanja, Grace
    Asio, Juliet
    Lutalo, Tom
    Namale, Alice
    Sanyu, Grace
    Ssewanyana, Isaac
    Gonzalez-Salazar, Jesus Fidel
    Nazziwa, Jamirah
    Nanyonjo, Maria
    Raizes, Elliot
    Kabuga, Usher
    Mwangi, Christina
    Kirungi, Wilford
    Musinguzi, Joshua
    Mugagga, Kaggwa
    Mbidde, Edward Katongole
    Kaleebu, Pontiano
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (09) : 2407 - 2414